Circumferential Viscodilation Ab Interno Combined with Phacoemulsification for Treatment of Open-Angle Glaucoma: 12-Month Outcomes
Received 8 March 2020
Accepted for publication 28 April 2020
Published 20 May 2020 Volume 2020:14 Pages 1357—1364
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Nathaniel Tracer,1 Jaime E Dickerson Jr,2,3 Nathan M Radcliffe4
1NYU School of Medicine, New York, NY, USA; 2Sight Sciences, Inc, Menlo Park, CA, USA; 3North Texas Eye Research Institute, UNTHSC, Fort Worth, TX, USA; 4Mt Sinai School of Medicine, New York, NY, USA
Correspondence: Nathan M Radcliffe
Mt Sinai School of Medicine, New York Eye Surgery Center, 1101 Pelham Parkway North, New York, NY, USA
Tel +1 718 519 1000
Purpose: To evaluate reduction in intraocular pressure (IOP) and medications for open-angle glaucoma (OAG) patients 12 months post-ab-interno circumferential viscodilation (VISCO360, Sight Sciences, Menlo Park, CA) in conjunction with cataract surgery.
Setting: Surgical center (New York, United States).
Design: Retrospective study of all OAG patients treated with 360-degree ab-interno viscodilation with cataract surgery by a single surgeon (NR) having 12 months of follow-up. Eyes were stratified by baseline IOP. Group 1: ≥ 18 mmHg (n=111). Group 2: < 18 mmHg (n=69).
Methods: IOP was measured using Goldmann applanation tonometry. Medications, the number of medication-free eyes in each group at 12 months, and adverse events (AE) are reported. Analysis includes descriptive statistics and t-tests evaluating change from baseline.
Results: Groups 1 and 2 had mean baseline IOP of 22 and 14.3 mmHg. Medication use was 0.9 and 1.1 for Groups 1 and 2. At 12 months IOP for Group 1 was reduced 22% to 17.2 mmHg (p< 0.0001) on 1.0 medications (p=0.7). IOP for Group 2 was similar to baseline (15.4 mmHg) but with a reduction in medications to 0.6 (p< 0.05). The proportion medication free at 12 months was 32% and 47% for Groups 1 and 2 versus 34% and 26% at baseline, respectively. There were few AE (hyphema 1.7%, IOP elevation > 10 mmHg > 30 days post-op 1.1%, mild inflammation < 1%) and no secondary surgical interventions excepting a single paracentesis, one-day postoperative.
Discussion: Treatment goals for the two groups differed. Pressure reduction (Group 1) or medication reduction (Group 2). Viscodilation achieved significant IOP reduction in Group 1 and medication reduction in Group 2 with many patients (both groups) medication free at 12 months. AE were infrequent and transient.
Conclusion: Circumferential ab-interno viscodilation can be combined with cataract surgery and provide an IOP lowering and medication reduction benefit sustained for at least 12 months, for many patients with OAG.
Keywords: viscodilation, MIGS, open-angle glaucoma, glaucoma surgery, VISCO360, canaloplasty, OMNI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]